Publications by authors named "R C Aller"
Article Synopsis
- A significant number of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) show indeterminate results from vibration-controlled transient elastography (VCTE), prompting the need for better diagnostic methods for significant fibrosis.
- A large study, involving 1196 MASLD patients from various centers, developed an algorithm that used liver stiffness measurements (LSM) and controlled attenuation parameters (CAP) to accurately identify significant fibrosis.
- The algorithm demonstrated high sensitivity and specificity in diagnosing significant fibrosis, potentially helping to identify treatment candidates for MASLD by re-allocating patients based on their risk levels.
Article Synopsis
- The study investigates how well non-invasive tests (NITs) can diagnose metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis in patients over 50 with Type 2 Diabetes and obesity.
- Out of 124 patients, a significant portion was found to have either early MASH or MASH with significant fibrosis, with the OWLiver Panel accurately classifying 86.1% of cases.
- Results indicate that the OWLiver Panel is an effective one-step screening tool for identifying MASH in high-risk individuals, outperforming combinations of different NITs.
Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
United European Gastroenterol J
October 2024
Article Synopsis
- The study aimed to evaluate the role of FGF21 in metabolic dysfunction-associated steatotic liver disease (MASLD) by analyzing both human samples and animal models.
- Significant increases in FGF21 gene expression and circulating levels were found in MASLD patients as well as in cell and animal models exposed to fatty acids.
- Additionally, the A-allele from the FGF21 rs838133 variant was linked to a higher risk of severe liver conditions in MASLD patients, indicating genetic factors may contribute to disease severity.
This is the summary report of the 5th Translational Hepatology Meeting, endorsed by the Spanish Association for the Study of the Liver (AEEH) and held in Seville, Spain, in October 2023. The meeting aimed to provide an update on the latest advances in the field of basic and translational hepatology, covering different molecular, cellular, and pathophysiological aspects of the most relevant clinical challenges in liver pathologies. This includes the identification of novel biomarkers and diagnostic tools, the understanding of the relevance of immune response and inflammation in liver diseases, the characterization of current medical approaches to reverse liver diseases, the incorporation of novel molecular insights through omics techniques, or the characterization of the impact of toxic and metabolic insults, as well as other organ crosstalk, in liver pathophysiology.
View Article and Find Full Text PDF